May 13, 2020
Treatment Potential of LPCN 1144 Demonstrated in a Pre-Clinical NASH and Hepatic Fibrosis Model
Jan 22, 2020
Metacrine Demonstrates Best-in-Class FXR Drug Program with Positive Clinical Results in NASH Patients
Nov 19, 2019
Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Oct 16, 2019
Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH
Aug 29, 2019
Global $61.6 Bn Non-Alcoholic Steatohepatitis (NASH) Drugs Market to 2028
Jul 10, 2019
The global primary biliary cholangitis therapeutics market at a CAGR of close to 10% during the forecast period
Jun 19, 2019
Global Ursodeoxycholic Acid Market to Surpass US$ 1,075.5 Million by 2026 - Coherent Market Insights
Apr 15, 2019
Mirum Pharmaceuticals Presents New Data Demonstrating Durable Improvements in Clinical Outcome Measures in Patients with PFIC2 and Alagille Syndrome Treated with Maralixibat
Mar 12, 2019
Galmed Reports Positive Results From Pharmacokinetic Split Dose Study of Aramchol
Nov 27, 2018
Nonalcoholic Steatohepatitis (NASH) Market Analysis, Market size, Epidemiology, Leading companies and Competitive Analysis by DelveInsight
Aug 03, 2018
Data Projects the NASH Market Will Eclipse USD 21 Billion by 2025
Jul 31, 2018
Non-Alcoholic Steatohepatitis (NASH) Market to Witness a CAGR of 58.4% During 2021 to 2025 - Allied Market Research
Dec 08, 2017
Nonalcoholic Steatohepatitis (NASH) Market Report to 2027
Oct 24, 2017
Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Oct 10, 2017
Non-Alcoholic Steatohepatitis Drugs Market (NASH) Trends, Size, Growth, Opportunities and 2026 Forecast Report
Sep 12, 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intercept Pharmaceuticals, Inc. - ICPT
Sep 11, 2017
Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)
Jun 06, 2017
Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)